Valuation Thermo Fisher Scientific, Inc.
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 446.45 USD | -0.30% |
|
-0.12% | -23.12% |
Company Valuation: Thermo Fisher Scientific, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 262,925 | 216,998 | 205,083 | 198,988 | 217,704 | 166,416 | - | - |
| Change | - | -17.47% | -5.49% | -2.97% | 9.41% | -23.56% | - | - |
| Enterprise Value (EV) 1 | 293,318 | 242,962 | 231,923 | 226,254 | 247,237 | 197,304 | 192,412 | 186,732 |
| Change | - | -17.17% | -4.54% | -2.44% | 9.27% | -20.2% | -2.48% | -2.95% |
| P/E ratio | 34.3x | 31.2x | 34.4x | 31.5x | 32.7x | 22.3x | 19.4x | 16.5x |
| PBR | 6.45x | 4.89x | 4.39x | 4x | - | 2.99x | 2.71x | 2.44x |
| PEG | - | -3.32x | -2.8x | 4.51x | 4.47x | 1.7x | 1.3x | 0.9x |
| Capitalization / Revenue | 6.71x | 4.83x | 4.79x | 4.64x | 4.89x | 3.48x | 3.3x | 3.11x |
| EV / Revenue | 7.48x | 5.41x | 5.41x | 5.28x | 5.55x | 4.13x | 3.82x | 3.49x |
| EV / EBITDA | 22.6x | 20.3x | 21.3x | 20.8x | 22.2x | 15.9x | 14.4x | 12.9x |
| EV / EBIT | 24.2x | 22.1x | 23.6x | 23.3x | 24.5x | 17.7x | 16x | 14.4x |
| EV / FCF | 41.8x | 35x | 33.5x | 30.9x | 39.3x | 27.6x | 21.5x | 19.7x |
| FCF Yield | 2.39% | 2.85% | 2.99% | 3.24% | 2.55% | 3.62% | 4.64% | 5.08% |
| Dividend per Share 2 | 1.04 | 1.2 | 1.4 | 1.56 | - | 1.843 | 1.939 | 2.08 |
| Rate of return | 0.16% | 0.22% | 0.26% | 0.3% | - | 0.41% | 0.43% | 0.46% |
| EPS 2 | 19.46 | 17.63 | 15.45 | 16.53 | 17.74 | 20.11 | 23.13 | 27.16 |
| Distribution rate | 5.34% | 6.81% | 9.06% | 9.44% | - | 9.16% | 8.38% | 7.66% |
| Net sales 1 | 39,211 | 44,915 | 42,857 | 42,879 | 44,556 | 47,776 | 50,376 | 53,503 |
| EBITDA 1 | 12,969 | 11,971 | 10,878 | 10,863 | 11,159 | 12,399 | 13,351 | 14,483 |
| EBIT 1 | 12,138 | 10,985 | 9,810 | 9,707 | 10,109 | 11,153 | 12,004 | 12,980 |
| Net income 1 | 7,725 | 6,950 | 5,995 | 6,335 | 6,704 | 7,337 | 8,192 | 9,172 |
| Net Debt 1 | 30,393 | 25,964 | 26,840 | 27,266 | 29,533 | 30,888 | 25,996 | 20,317 |
| Reference price 2 | 667.24 | 550.69 | 530.79 | 520.23 | 579.45 | 447.81 | 447.81 | 447.81 |
| Nbr of stocks (in thousands) | 394,048 | 394,048 | 386,372 | 382,500 | 375,708 | 371,621 | - | - |
| Announcement Date | 02/02/22 | 01/02/23 | 31/01/24 | 30/01/25 | 29/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 22.27x | 4.13x | 15.91x | 0.41% | 166B | ||
| 48.49x | 12.71x | 28.48x | -.--% | 156B | ||
| 26.49x | 5x | 15.58x | 0.9% | 118B | ||
| 20.96x | 4.18x | 13.67x | -.--% | 84.44B | ||
| 29.3x | 6.52x | 20.64x | -.--% | 47.31B | ||
| 17.84x | 2.07x | 10.57x | 2.94% | 43.8B | ||
| 35.59x | 5.73x | 17.46x | -.--% | 32.72B | ||
| 21.2x | 4.35x | 15.08x | 0.92% | 31.25B | ||
| 19.61x | 5.17x | 13.01x | 1.17% | 30.14B | ||
| 13.66x | 1.55x | 8.66x | 0.25% | 28.01B | ||
| Average | 25.54x | 5.14x | 15.91x | 0.66% | 73.87B | |
| Weighted average by Cap. | 28.64x | 6.15x | 17.89x | 0.51% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- TMO Stock
- Valuation Thermo Fisher Scientific, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















